Rabies is a deadly disease and endemic in over 100 countries. It causes around 59,000 human deaths annually, the vast majority in Asia and Africa. There are safe and effective human vaccines for pre- and post-exposure prophylaxis. With a prompt and proper post-exposure prophylaxis (PEP), exposed people have a survival rate close to 100%.
European Testing Week is a European campaign that encourages partner organisations, in community, health care and policy institutions, throughout Europe to unite for one week twice a year to increase testing efforts and promote awareness on the benefits of earlier hepatitis and HIV testing.
Nearly one in three foodborne outbreaks in the EU in 2018 were caused by Salmonella. This is one of the main findings of the annual report on trends and sources of zoonoses published today by the European Food Safety Authority (EFSA) and the European Centre for Disease Prevention and Control (ECDC).
Within one week, Latvia, Spain and Italy each notified a case of imported rabies. Earlier in the year, Norway had reported an additional travel-related case. Travellers to countries where rabies is enzootic should follow basic preventive measures.
Around the globe, more women than men live with HIV. Does the same apply to Europe? We will take a closer look at trends and risk factors for HIV among women.
Many women in the WHO European Region, particularly those in their 40s, are diagnosed at a late stage of HIV infection when their immune system is already starting to fail. They are three to four times more likely to be diagnosed late than younger women. According to data for 2018 released today by the European Centre for Disease Prevention and Control (ECDC) and the WHO Regional Office for Europe, women accounted for one-third of the 141 000 new HIV diagnoses in the Region, indicating that this population needs more attention in Europe's prevention and testing efforts.
On the way towards the Sustainable Development Goal (SDG) for health, Europe has one important battle to take on: reducing the proportion of those living with undiagnosed HIV and viral hepatitis. Current status in the EU/EEA: one in seven people living with HIV are unaware of their infection, up to four out of 5 people living with hepatitis B and three out of four people with hepatitis C infection have not yet been diagnosed.
This estimate on the “PrEP gap” in Europe was published in a paper in Eurosurveillance stating that 500 000 men who have sex with men in the European Union currently cannot access HIV pre-exposure prophylaxis (PrEP), despite being very likely to use it.
The recommendation from ECDC follows reports of falsified rabies vaccines and anti-rabies serum circulating in the Philippines and is aimed at travellers who have received the vaccine or serum after possible exposure to rabies.
In order to maximise the benefits of treatment for HIV or viral hepatitis, it is critical to test and diagnose people as soon as possible in the course of the infection. ECDC supports this objective of European Testing Week.